Ocean Biomedical Granted Patent Allowance For Malaria Antibodies
$OCEA
Biotechnology: Pharmaceutical Preparations
Health Care
Ocean Biomedical Granted Patent Allowance For Malaria Antibodies
Save time and jump to the most important pieces.
Gainers Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. The market value of their outstanding shares is at $7.1 million. Akanda (NASDAQ:AKAN) stock rose 7.74% to $2.92. The company's market cap stands at $5.5 million. LifeMD (NASDAQ:LFMD) stock rose 5.81% to $8.0. The market value of their outstanding shares is at $327.0 million. Purple Biotech (NASDAQ:PPBT) shares rose 5.79% to $0.58. The company's market cap stands at $15.2 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 5.29% to $0.44. The market value of their outstanding shares is at $2.0 million. Compass Therapeutics (NASDAQ:CMPX) shares increased by 4.95% to $1.27. The
As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with respect to filing of its 10-K for the year ended December 31, 2023.
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
PROVIDENCE, Rhode Island, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq Stock Market LLC ("Nasdaq") stating that on April 18, 2024, May 22, 2024, and August 19, 2024, Staff notified the Company that it did not comply with Nasdaq's filing requirements set forth in Listing Rule 5250(c)(1) (the "Rule") because it had not filed its Form 10-K for the year ended December 31, 2024 (the "Form 10-K"), and its Forms 10-Q for the periods ended March 31, 2024 and June 30, 2024 (the "Forms 10-Q"), respectively. Based on its review and the materials submitted on June 17, 2024 and
This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further the continuation of the program and the development of new YKL-40 inhibitors. The Bio-dollar value of the agreement is approximately $32 million Warsaw, 15 October 2024 – Molecure S.A., a clinical stage biotechnology company, leveraging unique competencies in medical chemistry and biology to discover and d
Ocean Biomedical's Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung Cancer, Glioblastoma, Prostate Cancer, Melanoma, and Breast Cancer Providence, RI, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that Scientific Co-founder Dr. Jack A. Elias, MD, PhD, and colleagues have published new research in the Journal of Immunology that expands understanding of how CHI3L1 inhibits the body's natural immune responses to lung cancers and related diseases such as chronic obstructive pulmonary disease (COPD). This research demonstrates for the first time the complex ways that CHI3L1 inhibits macropha
3 - Ocean Biomedical Holdings, Inc. (0001836612) (Issuer)